Introduction {#sec1}
============

*Cassia obtusifolia* Linn seeds have a long history of use in traditional Chinese medicine, where anthraquinones and naphthopyrones derivatives were reported as predominant constituents, particularly the glycosides (cassiaside, rubrofusarin gentiobioside, and cassiaside B).^[@ref1]^ Seed extracts and their constituents have been reported for activities such as anti-Alzheimer's disease,^[@ref2]−[@ref5]^ anti-Parkinson's disease,^[@ref6]^ antidiabetic and diabetic complications,^[@ref7],[@ref8]^ hepatoprotection,^[@ref9],[@ref10]^ anti-inflammation,^[@ref2]^ neuroprotective activity,^[@ref11],[@ref12]^ antibacterial,^[@ref13]^ and antioxidant.^[@ref14],[@ref15]^ In a previous study,^[@ref16]^ 100 μM emodin inhibited 4 nM (−)-epinephrine, 2 μM nicotinic acid, and 8 μM histamine-induced dynamic mass redistribution signals in human epidermoid carcinoma A431 cell, showing hydroxyl carboxylic acid receptor-2 (HCA-2), histamine receptor (H~1~R), and β2-adrenoceptor (β2-AR) as targets. Similarly, by upregulating glucocorticoid receptor (GR) and brain-derived neurotrophic factor (BDNF) levels in the hippocampus, emodin improved the depression-like behavior in chronic unpredictable mild stress-induced behavioral deficit (depression-like behavior) mice.^[@ref17]^ Emodin at 30 μM concentration showed an antipsychotic effect in Schizophrenia model (epidermal growth factor challenged primary neuronal cultures) by attenuating the receptor activation of ErbB1 and ErbB2.^[@ref18]^

Another anthraquinone, aloe-emodin, attenuated scopolamine-induced cognitive deficits by inhibiting the acetylcholinesterase activity (IC~50~ = 18.37 μg/mL) and modulating H~2~O~2~-induced oxidative stress in PC12 cells.^[@ref19]^ Likewise, in subcutaneous human glioblastoma U87MG-implanted nude CG1 mice, i.p. administration of aloe-emodin at 50 mg/(kg day) for 15 days showed antiproliferative effect by decreasing Ki67 positive cells and proapoptotic effect by increasing P53 and caspase 6 in mouse brain.^[@ref20]^ In the same study, aloe-emodin at 20 and 40 μM concentration induced cell cycle arrest in U87MG cells by increasing the expression levels of p53, p21, and the reduction of cyclin CDK2 *in vitro*.

More recently, we have reported the human monoamine oxidase (hMAO) inhibitory potential of *Cassia* seed-derived secondary metabolites^[@ref21]^ and a possible role of rubrofusarin against comorbid diabetes and depression *via* protein tyrosine phosphatase 1B and hMAO inhibition.^[@ref22]^ In that study,^[@ref21]^ emodin, alaternin (7-hydroxyemodin), aloe-emodin, and questin inhibited hMAO enzyme activity with low micromolar IC~50~ values ranging from 0.17 to 23 μM.

Drugs have specific targets in the body through which they modulate the disease state. Modern drug discovery and development incorporates *in silico* prediction approaches to predict the potential target proteins to understand the mechanism of action of drugs in addition to *in vitro* and *in vivo* studies.^[@ref23]^ G protein-coupled receptors (GPCRs) represent one of the most important drug targets with potential therapeutic benefits in the central nervous system (CNS) and endocrine systems. The concept of precise medication relies on GPCRs targeting, and to date, 34% of FDA-approved drugs are GPCR targets.^[@ref24]^ So, the main objectives of this study were to: (a) predict the main targets for *Cassia*-derived secondary metabolites in CNS *via* proteocheminformatics modeling (PCM), (b) validate the PCM prediction by evaluating the modulatory effect on predicted receptors *via* cell-based functional GPCRs assays, and (c) look at the specific binding interactions of test ligands ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) and target receptors *via* molecular docking simulation.

![Structure of anthraquinones from *Cassia obtusifolia* seeds.](ao0c00684_0006){#fig1}

Results and Discussion {#sec2}
======================

*In Silico* Target Prediction {#sec2.1}
-----------------------------

From PCM, the highest-ranked 20-potential protein targets were predicted for the four anthraquinones. [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} enlists the target proteins with the normalization rate. As shown in the table, V~1A~ receptor is on the top of the list followed by substance P and 5HT1A receptor, with the dopamine receptor also being placed within the 10 highest ranks. Based on this prediction, we then proceeded to validate the predictions in GPCRs cell-based functional assays with the dopamine (D~1~, D~3~, and D~4~), 5HT~1A~, and V~1A~ receptor ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}).

###### Twenty Most Highly Predicted Protein Targets Predicted from PCM Modeling for *Cassia*-Derived Anthraquinones in Neurodegenerative Diseases[a](#t1fn1){ref-type="table-fn"}

  organismal system   abbreviation   protein name                                                         NR
  ------------------- -------------- -------------------------------------------------------------------- --------
  STS                 V~1A~R         vasopressin V1A receptor                                             2.1742
  STS                 SPR            substance P receptor                                                 1.9936
  NS                  5-HT-1A        5-hydroxytryptamine receptor 1A                                      1.9824
  STS                 NKR            neuromedin-K receptor                                                1.9311
  STS                 OT-R           oxytocin receptor                                                    1.9099
  STS                 MAPK14         mitogen-activated protein kinase 14                                  1.8689
  STS, NS             5-HT-6         5-hydroxytryptamine receptor 6                                       1.8408
  NS                  DRD3           D3 dopamine receptor                                                 1.8323
  STS, NS             5-HT-2B        5-hydroxytryptamine receptor 2B                                      1.7906
  STS, NS             5-HT-4         5-hydroxytryptamine receptor 4                                       1.7508
  NS                  5-HT-1B        5-hydroxytryptamine receptor 1B                                      1.7354
  STS                 PI3K-α         phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic α-subunit   1.7316
  STS, NS             ACM5           muscarinic acetylcholine receptor M5                                 1.7278
  STS                 NTR1           neurotensin receptor type 1                                          1.7278
  STS, NS             DRD1           D1 dopamine receptor                                                 1.7278
  STS                 CysLTR1        cysteinyl leukotriene receptor 1                                     1.7128
  STS, NS             5-HT-2A        5-hydroxytryptamine receptor 2A                                      1.7128
  NS                  5-HT-3A        5-hydroxytryptamine receptor 3A                                      1.7128
  STS                 HSP90          heat shock protein HSP 90-α                                          1.7054
  NS                  ACM4           muscarinic acetylcholine receptor M4                                 1.6980

NR: Normalization rate; NS: Nervous system; STS: Signaling transduction system.

###### Efficacy Values (% Stimulation and % Inhibition) of Anthraquinones at Dopamine (D~1~, D~3~, and D~4~) and Serotonin (5HT~1A~) and Vasopressin (V~1A~) Receptors

                 emodin                          alaternin                      aloe-emodin                      questin                          reference drugs
  -------------- ------------------------------- ------------------------------ -------------------------------- -------------------------------- -----------------
  D~1~ (h)       --3.55 ± 0.64 (−10.20 ± 6.36)   0.01 ± 2.41 (−30.43 ± 8.95)    0.15 ± 4.45 (−47.85 ± 9.69)      --2.10 ± 0.85 (10.95 ± 6.01)     17 (3.6)
  D~3~ (h)       75.60 ± 12.87 (−10.8 ± 6.59)    43.97 ± 4.76 (−9.8 ± 4.82)     --57.95 ± 32.88 (20.60 ± 6.79)   34.85 ± 0.78 (1.25 ± 7.42)       4.0 (13)
  D~4~ (h)       2.35 ± 2.76 (−0.35 ± 4.03)      14.10 ± 0.31 (−2.4 ± 6.18)     -53.15 ± 7.00 (25.70 ± 15.70)    --38.15 ± 15.91 (4.50 ± 10.32)   5.8 (320)
  5-HT~1A~ (h)   --3.56 ± 0.21 (18.4 ± 3.89)     --5.46 ± 0.15 (34.50 ± 4.86)   3.45 ± 0.21 (1.55 ± 3.61)        2.45 ± 0.49 (0.70 ± 4.10)        1.6 (4.4)
  V~1A~ (h)      --4.80 ± 0.69 (69.35 ± 1.34)    --11.0 ± 0.66 (59.20 ± 0.10)   7.45 ± 1.20 (18.90 ± 9.05)       --3.40 ± 0.71 (16.30 ± 2.40)     0.29 (4.5)

\% stimulation and % inhibition of control agonist response at 50 μM of anthraquinones.

EC~50~ (nM) values of standard agonists (D1, D3, and D4: dopamine, 5-HT1A:serotonin, V1A: AVP).

IC~50~ (nM) values of standard antagonists (D1: SCH-23390, D3: (+)-butaclamol, D4: clozapine, 5-HT1A: (S)-WAY-100635, V1A: \[d(CH2)51, Tyr(Me)2\]-AVP).

Emodin, Alaternin, and Questin as Human Dopamine D~3~ (hD~3~R) Agonists {#sec2.2}
-----------------------------------------------------------------------

The effect of test compounds on dopamine receptor was evaluated fluorimetrically by measuring the level of cAMP. Agonist effect was expressed as % of the control response to 300 nM dopamine and antagonist effect was expressed as % inhibition of control response to 10 nM dopamine. As tabulated in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, 50 μM concentration of emodin, alaternin, and questin exhibited 75.6, 43.9, and 34.85% of control agonist response. The concentration-dependent agonist response is depicted in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A.

![Concentration-dependent percentage of control agonist effect (A) and percentage inhibition of control agonist effect (B, C) of emodin, alaternin, aloe-emodin, and questin on hD~3~R, hV~1A~R, and h5-HT~1A~R, respectively. ND: Not determined.](ao0c00684_0001){#fig2}

From the dose--response curve, half-maximal effective concentration (EC~50~) values of emodin and alaternin for hD~3~R were 21.85 ± 2.66 and 56.85 ± 4.59 μM, respectively. Dopamine had an EC~50~ value of 4 nM. The agonist effect of emodin at 12.5 μM was similar to that of 50 μM alaternin (*i.e*., approx. 45%). The potency of emodin was 2.5 times greater than that of alaternin as can be seen from the EC~50~ values of respective compounds.

Among central nervous system disorders, Parkinson's disease (PD) is the second most common age-related neurodegenerative disorder with 1% prevalence rate in the population above 60 years of age and is characterized by rigidity, tremor, and bradykinesia. The administration of dopamine in its prodrug form, levodopa ([l]{.smallcaps}-dopa), in combination with peripheral DOPA decarboxylase inhibitor is the current therapeutic approach to treat PD. However, owing to the side effects of [l]{.smallcaps}-dopa and the development of dyskinesia ([l]{.smallcaps}-dopa-induced dyskinesia; LID) upon prolonged use, an alternative treatment approach is warranted. Various studies have discovered the involvement of dopamine D~3~ receptors in the etiology of PD and LID. In PD, dopamine D~3~ receptor expression decreases, while it increases in the brain region of LID patients.^[@ref25]−[@ref28]^

To interpret the result of the functional assay, emodin and alaternin were docked into the D~3~R co-crystal structure (PDB ID: 3PBL) in complex with eticlopride. The docking result (binding pose and interacting residues) was confirmed by redocking with the reference agonist dopamine and rotigotine, and antagonist eticlopride. As shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} and tabulated in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, emodin was predicted to bind to the active site of dopamine D~3~R by forming three H-bonds with Ser196, Val111, and Thr115 at a distance of 2.0, 2.1, and 2.7 Å, respectively (shown by the blue lines in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). In addition, the methyl group at C-6 formed a π--alkyl interaction with Phe345 (5.03 Å). Aromatic ring C formed a π--anion interaction with Asp110, while ring A formed π-sulfur and π--π T-shaped interactions with Cys114 and Phe346, respectively ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C).

![Molecular docking of human dopamine D~3~ receptor (hD~3~R) binding with emodin and alaternin along with positive controls (A). Emodin (B, C) and alaternin (D, E) docked into the active cavity of hD~3~R. Emodin, alaternin, dopamine, and eticlopride are presented as orange, green, red, and black sticks, respectively. Hydrogen-bond interactions are presented as blue lines (B, D).](ao0c00684_0002){#fig3}

###### Binding Sites and Docking Scores of Emodin and Alaternin along with Reference Compounds in Human Dopamine D~3~ Receptor (hD~3~R)

  compounds                                                  binding energy (kcal/mol)                no. of H-bonds   H-bond interaction residues                    nonpolar interacting residues
  ---------------------------------------------------------- ---------------------------------------- ---------------- ---------------------------------------------- ----------------------------------------------------------------------------------------
  dopamine[a](#t3fn1){ref-type="table-fn"} (agonist)         --5.84                                   5                Asp110 (salt bridge), Val111, Thr115, Ser196   Val111, Cys114, Phe346
  rotigotine[a](#t3fn1){ref-type="table-fn"} (agonist)       --9.23                                   2                Asp110 (salt bridge), Ser192                   Val111, Phe345, His349, Val107, Cys181, Val111, Cys114
  eticlopride[a](#t3fn1){ref-type="table-fn"} (antagonist)   --8.50[b](#t3fn2){ref-type="table-fn"}   3                Asp110 (salt bridge), Asp110, His349           Val111, Cys114, Val189, Phe346, His349, Val111, Ile183, Phe345
  emodin                                                     --6.67                                   3                Ser192, Thr115, Val111                         Tyr373, Thr369, Tyr365, His349, Phe345, Phe346, Ile183, Trp342, Asp110, Cys114, Ser196
  alaternin                                                  --6.79                                   4                Tyr365, Ser196 Thr115, Val111                  Tyr373, Thr369, Tyr365, His349, Phe345, Phe346, Ile183, Trp342, Asp110, Cys114, Ser192

Dopamine, rotigotine, and eticlopride were used as reference ligands.

Root-mean-square deviation (RMSD) value: 0.48 Å.

Similarly, as shown by the blue lines in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}D, four H-bond interactions with Tyr365, Val111, Ser196, and Thr115 were predicted at a distance of 2.1, 2.1, 2.4 and 2.8 Å, respectively, for alaternin. The methyl group involved in π-alkyl interactions with Phe345 (5.11 Å) and Tyr373 (4.34 Å). In addition, similar to emodin, aromatic ring C formed a π-anion interaction with Asp110, while ring A formed π-sulfur and π--π T-shaped interactions with Cys114 and Phe346, respectively ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}E). From these docking results ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}), it was found that hydrophobic Phe345 and Phe346 residues of D~3~R are important for binding of ligands containing aromatic rings like emodin, alaternin, dopamine, and rotigotine. Conserved Asp and Ser residues also acted as bridges between emodin/alaternin and D~3~R *via* electrostatic and H-bond interaction, respectively.

Besides playing a central role in emotion and behavior, dopamine is responsible for the suppression of proinflammatory cytokines in macrophages, endothelial cells, neutrophils, mast cells, or glial cells, thereby regulating immune/inflammatory response.^[@ref29]−[@ref33]^ Likewise, in a recent study, dopamine suppressed inflammatory response and attenuated tissue injury in mice with acute pancreatitis^[@ref34]^ and attenuated lipopolysaccharide/[d]{.smallcaps}-galactosamine-induced fulminant liver injury in mice by suppressing the production of TNF-α phosphorylation of c-jun-N-terminal kinase (JNK); cleavage of caspase-3; upregulation of hepatic caspase-3, caspase-8, and caspase-9 activities; and reducing the count of terminal deoxynucleotidyl transferase-mediated nucleotide nick-end labeling (TUNEL)-positive hepatocytes.^[@ref35]^ Therefore, the hD~3~R agonist effect of emodin and alaternin might have a role for their reported anti-inflammatory effect.^[@ref36],[@ref37]^

Emodin and Alaternin as Human Vasopressin 1A Receptor (hV~1A~R) Antagonists {#sec2.3}
---------------------------------------------------------------------------

In human recombinant Chinese hamster ovary (CHO) cells expressing the hV~1A~ receptor, reference agonist arginine vasopressin (AVP) caused a concentration-dependent increase in intracellular Ca^2+^ concentration with an EC~50~ value of 0.29 nM ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B and [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). The test compounds emodin, alaternin, aloe-emodin, and questin did not show any effect on control agonist response. They did not show any agonist response up to 50 μM, and % of control agonist response was negative at 50 μM concentration ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). However, for antagonist effect, emodin and alaternin showed a concentration-dependent inhibition of control response to 10 nM AVP ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B). Even at 12.5 μM concentration, emodin and alaternin inhibited the 10 nM AVP-induced intracellular Ca^2+^ concentration by \>50%. The IC~50~ values for emodin and alaternin were 10.25 ± 1.97 and 11.51 ± 1.08 μM, respectively. The reference antagonist \[d(CH~2~)~5~^1^, Tyr(Me)~2~\]-AVP inhibited AVP-induced Ca^2+^ response with an IC~50~ value of 4.5 nM. The antagonist effect of aloe-emodin and questin was very weak with an approximately 17% inhibition of control agonist response at 50 μM concentration.

Similarly, previous studies on natural emodin had reported platelet aggregation inhibition^[@ref38]^ and vasorelaxant property.^[@ref39]^ V~1A~R in vascular smooth muscles is responsible for vasoconstriction, myocardial contractility, platelet aggregation, and uterine contraction.^[@ref40]^ Vasopressin receptor is another target for CNS drugs, and vasopressin antagonists represent a novel approach for the treatment of stress, mood, and behavioral disorders.^[@ref41]^

Intraperitoneal injection of emodin at a dose of 25 g/(kg day) in cerebral ischemia/reperfusion (I/R) model rats improved neurological deficit scores and reduced blood--brain barrier (BBB) permeability and infarction area, suggesting the inhibition of the expressions of connexin 43 and aquaporin 4 (AQP4) as a probable mechanism.^[@ref42]^ AQP4 is membrane water channel protein that plays an important role in the cerebral edema and brain water balance. A selective V~1A~R antagonist SR49059 prevented brain edema by suppressing injury-induced upregulation of GFAP, V~1A~R, and AQP4 after traumatic brain injury.^[@ref43]^

Vasopressin has numerous peripheral roles. An increased VP level along with impaired renal water excretion and abnormal renal hemodynamics in a mouse model of CCl~4~-induced liver cirrhosis has previously been reported.^[@ref44]^ Similarly, a recent study on ischemia-reperfusion injury mouse model^[@ref45]^ identified upregulated V~1~R expression in hepatocytes and highlighted the importance of the hepatocyte V~1~R/Wnt/β-catenin/FoxO3a/Akt pathway in hepatoprotection. From PCM modeling, V~1A~R was predicted as a top-target for *Cassia*-anthraquinones. And further validation of PCM prediction *via* cell-based functional assays in transfected cells expressing human cloned V~1A~R (CHO-V~1A~R), emodin, and alaternin was characterized as V~1A~R antagonists (IC~50~ = 10.25 ± 1.97 and 11.51 ± 1.08 μM, respectively). Therefore, the reported vasorelaxant and antiedema property of emodin might be attributed to its V~1A~R antagonist effect.

To further interrogate the structural basis of the antagonist mechanism of emodin and alaternin on the vasopressin receptor, compounds were docked into the homology model of V~1A~ receptor and the result (binding pose and interacting residues) was confirmed by redocking with the reference agonist arginine vasopressin (AVP) and antagonist SR49059. As shown in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"} and tabulated in [Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}, AVP bound to the active site of V~1A~R with a binding score −9.14 kcal/mol by forming five H-bond interactions with Asp202, Glu54, Asp112, and Ile330. Similarly, antagonist SR49059 displayed H-bond interactions with Gln131, Gln108, and Lys128 with a binding score of −8.98 kcal/mol. Emodin involved in four H-bond interactions with Met135, Gln131, Ala101, and Gly337 with a bond length of 2.0--2.6 Å (shown by the blue lines in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B).

![Molecular docking of human vasopressin V~1A~ receptor (hV~1A~R) binding with emodin and alaternin along with positive controls (A). Emodin (B, C) and alaternin (D, E) docked into the active cavity of hV~1A~R. Emodin, alaternin, and SR49059 are presented as orange, green, and black sticks, respectively. Agonist, AVP is presented as a red ribbon. Hydrogen-bond interactions are presented as blue lines (B, D).](ao0c00684_0003){#fig4}

###### Binding Sites and Docking Scores of Emodin and Alaternin along with Reference Compounds in the Modeled Human Vasopressin V~1A~ Receptor (hV~1A~R)

  compounds                                              binding energy (kcal/mol)   no. of H-bonds   H-bond interaction residues              nonpolar interacting residues
  ------------------------------------------------------ --------------------------- ---------------- ---------------------------------------- ------------------------------------------------------------------------
  AVP[a](#t4fn1){ref-type="table-fn"} (agonist)          --9.14                      5                Asp202, Glu54, Asp112, Ile330            Trp204, Ile330, Ala101, Ala334, Val132, Met135
  SR49059[a](#t4fn1){ref-type="table-fn"} (antagonist)   --8.98                      5                Gln131, Gln108, Lys128                   Phe307, Trp204, Val132, Met135, Met220, Ala334, Ala205, Gln131, Thr333
  emodin                                                 --6.36                      4                Met135, Gln131, Ala101, Gly337           Val100, Ala101, Ala334, Phe307, Trp304, Met135
  alaternin                                              --6.40                      5                Lys128, Gln131, Ser213, Val217, Gln311   Lys128, Met135, Met220, Phe189, Ala205

Arginine vasopressin (AVP) and (2*S*)1-{(2*R*,3*S*)-5-chloro-3-(2-chloro-phenyl)-1-(3,4-dimethoxybenzene-sulfonyl)-3-hydroxy-2,3-dihydro-1*H*-indole-2-carbonyl}pyrrolidine-2-carboxamide (SR49059) were used as reference ligands.

In addition, other nonpolar interactions such as π--π T-shaped (Phe307 and Trp304) and π-alkyl (Ala334, 5.25 Å) interactions were observed for aromatic rings A and C ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C). In the case of alaternin, five H-bond interactions with Lys128, Gln131, Ser213, Val217, and Gln311 at a distance of 1.8--3.0 Å were predicted with a binding score of −6.40 kcal/mol.

Aromatic rings were involved in π-alkyl interactions with Lys128 (5.43 Å) and Ala205 (4.73 Å), and π-sulfur interaction with Met220. Although the number of H-bond interactions for alaternin was greater than that of emodin, both showed similar binding energies. The binding sites for antagonist SR49059 and test compounds overlapped---i.e., interaction with polar residue Lys128 and Gln131 in TM III, nonconserved residue Ala334 in TM VII, and aromatic residue Phe307 at the bottom of the binding pocket in TM VI. The interaction with Ala334 and Phe307 plays an important role in binding V~1A~R selective ligands.^[@ref46]^

Alaternin as Human Serotonin-1A Receptor (h5-HT~1A~R) Antagonists {#sec2.4}
-----------------------------------------------------------------

The antagonist effect of alaternin on h5-HT~1A~ receptor was evaluated fluorimetrically by measuring the free cytosolic Ca^2+^-ion concentration in response to 30 nM serotonin. [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C illustrates a concentration-dependent inhibitory effect of alaternin on the control agonist (30 nM serotonin) response along with the 50% inhibitory concentration. As shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, alaternin showed 34.5% inhibition of 30 nM serotonin effect at 50 μM and gave an IC~50~ value of 84.23 ± 4.12 μM ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C). The reference antagonist (S)-WAY-100635 had an IC~50~ value of 4.4 nM. Emodin, aloe-emodin, and questin remained ineffective in antagonizing the h5-HT~1A~ receptor activity.

In a recent study, emodin improved cycloheximide-induced amnesia in rats, and the authors suggested the blocking of serotonin release or activating the presynaptic 5-HT~1A~ receptor and muscarinic receptor as a possible mechanism.^[@ref47]^ However, for the particular effect measured here, we did not observe an effect on 5HT~1A~ receptor. In a previous study,^[@ref48]^*Cassia* seed extract at 20 μg/mL showed a significant antiallergic effect in IgE-mediated mast cells and anaphylactic models by inhibiting the production of IL4 (*p* \< 0.05), TNF (*p* \< 0.01), PGE2 secretion (*p* \< 0.01), and histamine release (*p* \< 0.01). Serotonin is one of the putative inflammatory mediators that is able to induce dose-dependent nociceptive behaviors when injected into the paw, and also appears to interact synergistically with other inflammatory mediators to generate pain.^[@ref49]^ In a study on subcutaneous formalin-injected paw model of pain,^[@ref50]^ coadministration of 5-HT~1A~ receptor antagonist WAY 100 135 (450 μg/paw) inhibited the phase 2 (long lasting) intense flinching behavior significantly (*P* \< 0.001). Similarly, the analgesic effect of electroacupuncture on inflammatory pain in the rat model of collagen-induced arthritis was blocked by a 5-HT~1A~ receptor antagonist spiroxatrine (1 mg/kg i.p.).^[@ref51]^

In a previous report, alaternin attenuated neuronal cell death in transient cerebral hypoperfused mice *via* anti-inflammatory responses by preventing nitrotyrosine and lipid peroxidation as well as inhibiting nitric oxide synthase expression.^[@ref37]^ There has been a well-reported correlation between 5-HT~1A~ receptor mRNA expression and neuroinflammation.^[@ref52],[@ref53]^ The expression of the 5-HT~1A~ receptor mRNA was enhanced in spinal GABA and enkephalin neurons after inflammation.^[@ref54]^ We observed a moderate antagonist effect of alaternin in 5-HT~1A~R (IC~50~: 84.23 ± 4.12 μM). This corroborates the reported anti-inflammatory effect of alaternin.

In the functional assay, only alaternin showed a moderate antagonist effect on h5-HT~1A~R for which we hence performed docking. As tabulated in [Table [5](#tbl5){ref-type="other"}](#tbl5){ref-type="other"}, the 3-OH group of emodin and alaternin displayed a H-bond interaction with Cys187 ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B,D). Similarly, the same π--π T-shaped interaction with Phe112, π--π stacked interaction with Phe361, and π-anion interaction with Asp116 were observed for both the test compounds ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C,E). However, additional nonpolar interaction between the 7-OH group and Trp358 was observed for alaternin ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B). This additional interaction could explain the potency of alaternin compared to that of emodin. However, further experimental analysis is needed to confirm the role of Trp358 in h5-HT~1A~ antagonism.

![Molecular docking of human 5-hydroxytryptamine~1A~ receptor (h5HT~1A~R) binding with emodin and alaternin along with positive controls (A). Emodin (B, D) and alaternin (C, E) docked into the active cavity of h5HT~1A~R. Emodin, alaternin, serotonin, and WAY 00635 are presented as orange, green, red, and black sticks, respectively. Hydrogen-bond interactions are presented as blue lines (B, D).](ao0c00684_0004){#fig5}

###### Binding Sites and Docking Scores of Emodin and Alaternin along with Reference Compounds in the Modeled of Human 5-hydroxytryptamine 1A Receptor (h5HT~1A~R)

  compounds                                                 binding energy (kcal/mol)   no. of H-bonds   H-bond interaction residues            nonpolar interacting residues
  --------------------------------------------------------- --------------------------- ---------------- -------------------------------------- --------------------------------------------------------------
  serotonin[a](#t5fn1){ref-type="table-fn"} (agonist)       --6.77                      4                Asp116 (salt bridge), Thr200, Thr121   Ala203, Val117, Phe362, Phe361, Cys120
  WAY 100635[a](#t5fn1){ref-type="table-fn"} (antagonist)   --11.22                     3                Asp116 (salt bridge), Asn386           Ala93, Tyr96, Thr200, Phe112, Cys120, Ala203, Pbe362, Phe361
  emodin                                                    --7.01                      1                Cys187                                 Asp116, Ile189, Phe112, Phe361
  alaternin                                                 --6.77                      1                Cys187                                 Asp116, Ile189, Phe112, Phe361, Trp358

Serotonin and *N*-{2-\[4-(2-methoxyphenyl)-1-piperazinyl\]-ethyl}-*N*-(2-pyridinyl) cyclohexanecarboxamide (WAY 100635) were used as reference ligands.

Drug-likeness and ADME Prediction {#sec2.5}
---------------------------------

Drug-likeness was predicted for emodin, alaternin, aloe-emodin, and questin. The results in [Table [6](#tbl6){ref-type="other"}](#tbl6){ref-type="other"} suggested that these compounds have good druglike properties, as they adhered to the MDDR-like rule^[@ref55]^ and Lipinski's rule.^[@ref56]^ All anthraquinones were predicted midstructures in MDDR-like rule and suitable for drug development from Lipinski's rule. In ADME prediction, all compounds were predicted with strong plasma protein binding (91--100%), good human intestinal absorption (HIA) (75--94%), and good lipophilicity (log *P*~o/w~ value range, 1.89--2.69), indicating the suitability for CNS delivery. Likewise, the blood--brain barrier (BBB) penetration values (\[brain\]/\[blood\]) were \>0.45% indicating moderate absorption by the CNS.

###### Drug-likeness and ADME Characteristics as Predicted by PreADMET

                drug-likeness   ADME characteristics                          
  ------------- --------------- ---------------------- ------ ------- ------- -------
  emodin        midstructure    suitable               2.56   100     90.43   0.668
  alaternin     midstructure    suitable               2.57   98.17   75.71   0.459
  aloe-emodin   midstructure    suitable               1.89   91.11   90.64   0.492
  questin       midstructure    suitable               2.69   96.06   94.04   0.730

The log of the coefficient of solvent partitioning between 1-octanol and water.

Plasma protein binding (PPB) (\<90% represents weak binding, and \>90% represents strong binding).

Human intestinal absorption (HIA) (0--20%: poor, 20--70%: moderate, and 70--100%: good).

Absorption by the CNS \<0.1: low, 0.1--2.0: moderate, and \>2.0: high.

Overall, drug-likeness and ADME prediction results demonstrated that the test anthraquinones are suitable for CNS delivery. In general, relatively higher lipophilicity provides better CNS penetration; however, too high values may enhance nonspecific plasma protein binding.^[@ref57]^ The lipophilicity values log* P*/log* D* ranging from 1.7 to 2.8 demonstrate the highest CNS penetration,^[@ref58],[@ref59]^ and the values for the test anthraquinones in the present study fall within this range. The HIA rate was predicted to be good for all of the compounds, indicating the suitability for oral administration. However, in a previous report,^[@ref60]^ oral administration of emodin at doses of 20 and 40 mg/kg rapidly underwent phase II metabolism to form its glucuronide, and the parent form of emodin was almost undetectable *in vivo*. Therefore, oral administration would not be the best method of application of emodin because of fast elimination and low bioavailability *in vivo*. All of these predicted results will be helpful for the optimization of druglike properties.

High-throughput screening of chemical compounds had predicted quinone derivatives as reactive and pan assay interference compounds (PAINS) that could show a false biological effect.^[@ref61],[@ref62]^ However, this effect cannot be generalized for all of the quinone derivatives and structure--activity relationships would be evidence.^[@ref61]^ The basic chemical structure of the test compounds is anthracene-9,10-dione with different substituents at ortho-, meta-, and para-positions of two side rings ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). The effect of the test compounds on test receptors varied with substitution ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). When an anthracene-9,10-dione moiety had a polyhydroxy group at positions C1, C3, and C8 with methylation at position C6 (emodin), it showed potent agonist effect at dopamine hD~3~R and antagonist effect at hV~1A~R. However, an additional hydroxyl group at position C7 of emodin (as in alaternin) retarded the hD~3~R agonist effect without altering the antagonist effect at hV~1A~R. Besides, a moderate antagonist effect at h5-HT~1A~R was observed for alaternin, which was not observed for emodin. Similarly, a dihydroxy group at position C1 and C8, and a hydroxymethyl group at C6 position in an anthracene-9,10-dione moiety (aloe-emodin) showed mild antagonist effect at hD~3~R and hD~4~R. The hD~3~R agonist effect and hV~1A~R antagonist effect showed by emodin and alaternin was completely abolished in aloe-emodin. Interestingly, when an anthracene-9,10-dione moiety had a dihydroxy group at position C3 and C8, methyl group at position C6 and methoxy group at the C1 position, questin selectively modulated the hD~3~R agonist effect. From this structure--activity relation, the following insights can be drawn---(1) hydroxyl group at C1, C3, and C8 and a methyl group at C6 are essential for hD~3~R agonist and hV~1A~R antagonist effects; (2) an additional hydroxyl group at C7 of emodin is functional for the h5-HT~1A~R antagonist effect.

If all quinone derivatives are PAINS indeed, then all of the test anthraquinones of the present study should show functional effect in all of the tested receptors. However, only emodin and alaternin (7-hydroxyemodin) showed a selective agonist effect on dopamine D~3~R and antagonist effect on vasopressin V~1A~R, meaning these two compounds selectively bind to the particular receptor for functional effect. This clearly shows that the functional effect of emodin and alaternin is attributed to the substituents in the anthraquinone structure rather than quinone itself. Still, these effects need to be proved *in vivo*. Still, these effects need to be proved *in vivo*.

Conclusions {#sec3}
===========

In conclusion, the present study demonstrates the effect of emodin, alaternin (7-hydroxyemodin), aloe-emodin, and questin from *C. obtusifolia* seeds on various GPCRs (hD~1~R, hD~3~R, hD~4~R, h5-HT~1A~R, and hV~1A~R) modulation *via* cell-based functional assays and corroborate with the PCM prediction. Results characterize emodin and alaternin as dopamine D~3~R agonists and vasopressin V~1A~ antagonists. Questin showed a moderate hD~3~R agonist effect, and aloe-emodin showed mild hD~3~R antagonist effect. Only alaternin was effective in antagonizing h5-HT~1A~R, and the remaining compounds remained ineffective. Thus, we conclude that anthraquinones, especially emodin and alaternin appear to be an attractive therapeutic route for neuroprotection that has a beneficial effect on the aminergic pathways involved in neurodegeneration.

Materials and Methods {#sec4}
=====================

Chemicals and Reagents {#sec4.1}
----------------------

A murine interleukin-3-dependent pro-B (Ba/F3) and a transfected Chinese hamster ovary (CHO) cell lines were obtained from Eurofins Scientific (Le Bois I'Eveque, France). Dulbecco's modified Eagle's medium (DMEM) buffer, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, and Hank's balanced salt solution (HBSS) buffer were purchased from Invitrogen (Carlsbad, CA). The reference agonists (dopamine, serotonin, and arginine vasopressin) and antagonists (SCH-23390, (+)-butaclamol, clozapine, (S)-WAY-100635, and \[d(CH~2~)~5~,^[@ref1]^ Tyr(Me)~2~\]-AVP) were obtained from Sigma-Aldrich (St. Louis, MO). All of the drugs, chemicals, and reagents were of the highest grade available.

Isolation of Compounds {#sec4.2}
----------------------

Details on plant material, extraction, fractionation, isolation, and identification have been described in our recent work.^[@ref21]^ The purity of these compounds was considered to be \>98%, as evidenced by spectroscopic data (NMR and MS).

*In Silico* Prediction of Targets {#sec4.3}
---------------------------------

To predict potential protein targets for the four anthraquinones, a proteocheminformatics modeling (PCM) *in silico* target prediction method was employed. The model was trained on the chemical and biological similarities of 55 079 compounds active and inactive against 99 human proteins (11 537 active pairs vs 43 542 inactive pairs). Machine learning algorithm, in this case, Parzen Rosenblatt Windows (PRW)^[@ref63],[@ref64]^ was utilized to evaluate the patterns that differentiate between active and inactive complexes. Based on the patterns established, the activity of novel compounds against the 99 protein targets can be predicted. Chemical structures were represented as ECFP_4 fingerprint,^[@ref65]^ and chemical similarities were calculated using Aitchison--Aitken kernel.^[@ref66]^ Protein vectors were represented by their full sequence where a protein sequence is denoted as a string of characters, and each character represents an amino acid that is part of the protein. Prior to calculating the similarities between two protein sequences, the sequences are subjected to alignment using MUSCLE,^[@ref67]^ performed using the bio3d package.^[@ref68]^ The model was internally and externally validated by sensitivity values of 0.6837 and 0.4492, respectively. For full information on the model, readers are directed to a previous report.^[@ref23]^

GPCR Functional Assay for Human Dopamine Receptor {#sec4.4}
-------------------------------------------------

The effect of test compounds at human dopamine (D~1~, D~3~, and D~4~) receptors expressed in CHO cells was evaluated by measuring their effect on cAMP modulation *via* homogeneous time-resolved fluorescence (HTRF), as described previously.^[@ref69]^ Agonist activity was determined by measuring the effect on cAMP modulation, and antagonist activity by measuring the effect on agonist-induced cAMP modulation using the HTRF detection method. The cellular agonist effect was calculated as the percentage of the control response to dopamine for each receptor (D~1~, D~3~, and D~4~) targets, and the cellular antagonist effect was calculated as the percentage inhibition of the dopamine response for each target. To validate the result, reference antagonist SCH-23390, (+)-butaclamol, and clozapine were used for D~1~, D~3~, and D~4~ receptors, respectively.

GPCR Functional Assay for Human Serotonin 5-HT~1A~ and Vasopressin V~1A~ Receptor {#sec4.5}
---------------------------------------------------------------------------------

The agonist activity of test compounds at the human 5-HT~1A~ receptor expressed in Ba/F3 cells and V~1A~ receptor expressed in transfected CHO cells was determined by measuring their effect on cytosolic Ca^2+^-ion mobilization using a fluorimetric detection method described in our previous reports.^[@ref70],[@ref71]^ For antagonist activity, the effect on agonist-induced cytosolic Ca^2+^-ion mobilization was measured.

Cellular agonist effect at 5-HT~1A~ receptor was calculated as the percentage of the control response to serotonin (2.5 μM), and the antagonist effect was calculated as the percentage inhibition of the control response to 30 nM serotonin. To validate the result, reference antagonist (S)-WAY-100635 was employed. Similarly, for the cellular agonist at V~1A~ receptor, the percentage of the control response to 1 μM AVP was determined, and for antagonist effect, percentage inhibition of control response to 10 nM AVP was recorded. The standard reference antagonist \[d(CH~2~)~5~1 Tyr(Me)~2~\]-AVP was used to validate the result.

Homology Modeling and Molecular Docking {#sec4.6}
---------------------------------------

The primary sequence of the human 5HT~1A~R and human V~1A~R was obtained from UniProt (ID: P08908 and P37288, respectively). 5-HT~1B~ receptor (PDB 5V54) and μ-opioid receptor (4DKL) structures were obtained from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB) and used as a template for homology modeling of 5HT~1A~ and V~1A~ receptors, respectively. Modeling was conducted through SWISS-MODEL and refined through ModRefiner server (RMSD = 1.264 Å for 5HT~1A~R and 0.645 Å for V~1A~R).^[@ref72]^ Likewise, X-ray crystallography of a human dopamine D~3~ receptor (hD3R)--eticlopride complex (PDB ID: 3PBL) at a resolution 2.89 Å was obtained from the PDB.^[@ref73]^ The three-dimensional (3D) structures of emodin, alaternin, aloe-emodin, and questin were obtained from the PubChem Compound database (NCBI), with compound CIDs of 3220, 12548, 10207, and 160717, respectively. The docking of the target proteins and active compounds was successfully simulated using the AutoDock 4.2 program.^[@ref74]^ Automated docking simulations were performed using AutoDockTools (ADT) to assess appropriate binding orientations. For the docking calculations, Gasteiger charges were added by default, rotatable bonds were set by ADT, and all torsions were allowed to rotate. Grid maps were generated by AutoGrid. The docking protocol for rigid and flexible ligand docking consisted of 20 independent genetic algorithms; the other parameters used were the ADT defaults. The results were visualized and analyzed using Discovery Studio (v17.2, Accelrys, San Diego, CA) and PyMOL (v1.7.4, Schrödinger, LLC, Cambridge, MA).

Drug-likeness and ADME Prediction {#sec4.7}
---------------------------------

Drug-likeness predictions were carried out with PreADMET (v2.0, Yonsei University, Seoul, Korea). This web-based server can be used to predict absorption, distribution, metabolism, and excretion (ADME) data and build a drug-likeness library in silico.

Statistics {#sec4.8}
----------

All results are expressed as mean ± standard deviation (SD) of triplicate samples. Statistical significance was analyzed using one-way analysis of variance (ANOVA) (Systat Inc., Evaston, IL) and was noted at *p* \< 0.05.
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